Britain and America have forged a major commercial pact that will keep no tariffs on British drug exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to increase expenditure on drugs through the public health system. This pledge guarantees that import taxes on these key products will remain at nothing for a period of 36 months.
This deal is in response to earlier threats to significantly raise import taxes on patented drug imports, with increases floated up to one hundred percent.
"This agreement with the United Kingdom strengthens the global environment for cutting-edge drugs and introduces long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Trade Significance
Pharmaceuticals represent one of the UK's biggest goods shipped to the United States, which is clearly the largest market for large UK drugmakers.
Trade data indicate that in the one-year period to the end of the third quarter, the UK shipped medicines valued at billions to the US. This amount represented nearly one-fifth of British export trade in that timeframe.
"This agreement safeguards jobs, boosts funding and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary commented.
Detailed UK Commitments
The pact involves several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase overall health service expenditure on treatments from 0.3 percent of GDP to 0.6% over the following ten-year period.
- Refund Ceiling: The percentage drug companies must pay back to the NHS to control costs will be limited at 15%. Last year, rebates topped 20%.
Recent Tensions
The deal follows a ongoing tension between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
The disagreement were intensified by claims that American customers were charged a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward projects in the United States.
The Science Minister stated that the NHS needed to spend more on medicines, noting that its spending on drugs had decreased as a proportion of its overall budget over the last ten years.
